Literature DB >> 22942909

Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer.

Anastasios Dimou1, Konstantinos N Syrigos, Muhammad Wasif Saif.   

Abstract

Pancreatic cancer has historically proven resistant to anticancer agents. On the one hand, drugs might be more efficient if higher levels could be achieved at the tumor site rather than the normal tissues. On the other hand, the thick stroma and the relative absence of abundant vessels may account at least partially for the failure of successive clinical trials to demonstrate effective treatments in this type of malignancy. In this context, the development and testing in clinical trials of treatment strategies that aim to optimize drug delivery is an important target in improving the prognosis of patients with pancreatic cancer.

Entities:  

Keywords:  chemotherapy; drug delivery; folfirinox; gemcitabine; pancreatic cancer; resistance

Year:  2012        PMID： 22942909      PMCID： PMC3424495          DOI： 10.1177/1758834012446008

Source DB:  PubMed          Journal:  Ther Adv Med Oncol        ISSN： 1758-8340            Impact factor:   8.168


  44 in total

1.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

2.  Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis.

Authors:  Sanjib Bhattacharyya; Resham Bhattacharya; Steven Curley; Mark A McNiven; Priyabrata Mukherjee
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-02       Impact factor: 11.205

3.  Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.

Authors:  Daniel D Von Hoff; Ramesh K Ramanathan; Mitesh J Borad; Daniel A Laheru; Lon S Smith; Tina E Wood; Ronald L Korn; Neil Desai; Vuong Trieu; Jose L Iglesias; Hui Zhang; Patrick Soon-Shiong; Tao Shi; N V Rajeshkumar; Anirban Maitra; Manuel Hidalgo
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

4.  Curcumin induces DNA damage and caffeine-insensitive cell cycle arrest in colorectal carcinoma HCT116 cells.

Authors:  Jin-Jian Lu; Yu-Jun Cai; Jian Ding
Journal:  Mol Cell Biochem       Date:  2011-04-28       Impact factor: 3.396

5.  Enhanced distribution of NK012, a polymeric micelle-encapsulated SN-38, and sustained release of SN-38 within tumors can beat a hypovascular tumor.

Authors:  Yohei Saito; Masahiro Yasunaga; Junichiro Kuroda; Yoshikatsu Koga; Yasuhiro Matsumura
Journal:  Cancer Sci       Date:  2008-04-21       Impact factor: 6.716

6.  Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent.

Authors:  Chitta Ranjan Patra; Resham Bhattacharya; Enfeng Wang; Aaron Katarya; Julie S Lau; Shamit Dutta; Michael Muders; Shanfeng Wang; Sarah A Buhrow; Stephanie L Safgren; Michael J Yaszemski; Joel M Reid; Matthew M Ames; Priyabrata Mukherjee; Debabrata Mukhopadhyay
Journal:  Cancer Res       Date:  2008-03-15       Impact factor: 12.701

7.  Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis.

Authors:  Eric A Murphy; Bharat K Majeti; Leo A Barnes; Milan Makale; Sara M Weis; Kimberly Lutu-Fuga; Wolfgang Wrasidlo; David A Cheresh
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-07       Impact factor: 11.205

8.  Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas.

Authors:  Adrian M Senderowicz; John R Johnson; Rajeshwari Sridhara; Paul Zimmerman; Robert Justice; Richard Pazdur
Journal:  Oncology (Williston Park)       Date:  2007-12       Impact factor: 2.990

9.  A paracrine requirement for hedgehog signalling in cancer.

Authors:  Robert L Yauch; Stephen E Gould; Suzie J Scales; Tracy Tang; Hua Tian; Christina P Ahn; Derek Marshall; Ling Fu; Thomas Januario; Dara Kallop; Michelle Nannini-Pepe; Karen Kotkow; James C Marsters; Lee L Rubin; Frederic J de Sauvage
Journal:  Nature       Date:  2008-08-27       Impact factor: 49.962

10.  Coexpression of EGFR and HER-2 in pancreatic ductal adenocarcinoma: a comparative study using immunohistochemistry correlated with gene amplification by fluorescencent in situ hybridization.

Authors:  Jane Dancer; Hidehiro Takei; Jae Y Ro; Mary Lowery-Nordberg
Journal:  Oncol Rep       Date:  2007-07       Impact factor: 3.906
View more
  18 in total

Review 1.  Use of nano engineered approaches to overcome the stromal barrier in pancreatic cancer.

Authors:  Huan Meng; Andre E Nel
Journal:  Adv Drug Deliv Rev       Date:  2018-06-26       Impact factor: 15.470

2.  Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model.

Authors:  Jing Zhang; Lei Miao; Shutao Guo; Yuan Zhang; Lu Zhang; Andrew Satterlee; William Y Kim; Leaf Huang
Journal:  J Control Release       Date:  2014-03-15       Impact factor: 9.776

3.  A bioengineered heterotypic stroma-cancer microenvironment model to study pancreatic ductal adenocarcinoma.

Authors:  Cole R Drifka; Kevin W Eliceiri; Sharon M Weber; W John Kao
Journal:  Lab Chip       Date:  2013-10-07       Impact factor: 6.799

4.  Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer.

Authors:  Xiangsheng Liu; Paulina Lin; Ian Perrett; Joshua Lin; Yu-Pei Liao; Chong Hyun Chang; Jinhong Jiang; Nanping Wu; Timothy Donahue; Zev Wainberg; Andre E Nel; Huan Meng
Journal:  J Clin Invest       Date:  2017-04-17       Impact factor: 14.808

5.  Matrix stiffness mediates pancreatic cancer chemoresistance through induction of exosome hypersecretion in a cancer associated fibroblasts-tumor organoid biomimetic model.

Authors:  Weikun Xiao; Mahsa Pahlavanneshan; Chae-Young Eun; Xinyu Zhang; Charlene DeKalb; Bayan Mahgoub; Hanaa Knaneh-Monem; Sana Shah; Alireza Sohrabi; Stephanie K Seidlits; Reginald Hill
Journal:  Matrix Biol Plus       Date:  2022-05-16

Review 6.  Status and future directions in the management of pancreatic cancer: potential impact of nanotechnology.

Authors:  Catherine M Sielaff; Shaker A Mousa
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-02       Impact factor: 4.553

7.  Nanoparticle delivery of an AKT/PDK1 inhibitor improves the therapeutic effect in pancreatic cancer.

Authors:  Armando Lucero-Acuña; Justin J Jeffery; Edward R Abril; Raymond B Nagle; Roberto Guzman; Mark D Pagel; Emmanuelle J Meuillet
Journal:  Int J Nanomedicine       Date:  2014-12-03

Review 8.  Modulation of the tumor microenvironment for cancer treatment: a biomaterials approach.

Authors:  Isaac M Adjei; Sharma Blanka
Journal:  J Funct Biomater       Date:  2015-02-17

Review 9.  Pancreatic Cancer Chemoresistance to Gemcitabine.

Authors:  Manoj Amrutkar; Ivar P Gladhaug
Journal:  Cancers (Basel)       Date:  2017-11-16       Impact factor: 6.639

Review 10.  MicroRNAs in Metastasis and the Tumour Microenvironment.

Authors:  Carla Solé; Charles Henderson Lawrie
Journal:  Int J Mol Sci       Date:  2021-05-04       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.